OncoMatch/Clinical Trials/NCT05536141
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Is NCT05536141 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including casdatifan and Cabozantinib for clear cell renal cell carcinoma.
Treatment: casdatifan · Cabozantinib · Zimberelimab · Ipilimumab — The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Renal Cell Carcinoma
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: hypoxia inducible factor (HIF)-2α inhibitor
prior treatment with an hypoxia inducible factor (HIF)-2α inhibitor
Cannot have received: (cabozantinib)
For the casdatifan + cabozantinib combination cohort, any prior treatment with cabozantinib
Cannot have received: systemic treatment
For casdatifan + zimberelimab and casdatifan + zimberelimab + ipilimumab cohorts, any prior systemic treatment when cancer is present
Lab requirements
Kidney function
creatinine clearance ≥ 40 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- University of California at San Diego · San Diego, California
- UCLA · Santa Monica, California
- University of Miami · Miami, Florida
- Emory University · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05536141 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hypoxia inducible factor (HIF)-2α inhibitor, , systemic treatment disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages